Cancer treatment is increasingly assessed not only by how much a tumor shrinks, but also by how well the therapy is tolerated, how active and independent the patient remains, and how the immune system is affected. These were the areas examined in a report prepared at the Adjara Oncology Center in Batumi. The researchers compared patients receiving chemotherapy alone with patients who received chemotherapy together with Kamelin-M2 capsules.
The topic of “Camelyn M2 and chemotherapy” attracts considerable interest, but the figures, methods and limitations must be read calmly and critically. A single study can provide an important signal, but it does not automatically constitute definitive proof of efficacy.
The report describes an observation conducted from September 2007 to January 2011. It included 118 hospitalized patients with pathologically or cytologically confirmed malignant tumors at an intermediate or advanced stage. The population was heterogeneous: patients had lung, stomach, rectal, esophageal, breast and liver cancer, as well as malignant lymphoma. The mean age was 56.5 years, and participants were eligible if their Karnofsky score was above 60.
From a patient’s perspective, it is important that the researchers did not assess tumor response alone. They also examined selected markers of cellular immunity, body weight, Karnofsky performance status and peripheral blood counts. This gave the question of “Camelyn M2 and chemotherapy” a broader clinical context. At the same time, a large number of outcomes creates additional statistical questions and requires cautious interpretation.
According to the report, patients were randomly divided into two groups. The treatment group included 58 people and received chemotherapy together with Kamelin-M2. The control group included 60 people and received chemotherapy alone. In the treatment group, three capsules were taken daily. One course consisted of 60 capsules, and the authors described three courses separated by five- to seven-day breaks. First- or second-line chemotherapy regimens were selected according to the type of cancer and the standards in use at the time.
The word “randomized” is important because random allocation can reduce differences between groups. However, the report does not explain how the random sequence was generated, whether allocation was concealed, or whether any blinding was used. It is also unclear whether the clinicians assessing treatment response knew which group each participant was in. The absence of these details does not prove that the study was conducted incorrectly, but it makes the risk of bias harder to judge.
The authors assessed response according to WHO criteria. Complete response, abbreviated as CR, meant that all visible disease disappeared for at least four weeks. Partial response, or PR, meant that the product of the two largest perpendicular tumor diameters decreased by more than half, with no new lesions. “Effectiveness” was defined as the combined rate of CR and PR.
In the combined-treatment group, there were five complete responses and 17 partial responses: 22 responses among 58 participants, or 37.93%. In the control group, there were two complete responses and 11 partial responses: 13 responses among 60 participants, or 21.66%. The difference was approximately 16.3 percentage points, and the report gives a p-value below 0.05.
These figures deserve attention, but they should not be translated into the claim that the product “treats cancer.” Every participant received chemotherapy; the study compared standard treatment alone with standard treatment plus the investigated product. The report did not present overall survival, time to progression or long-term follow-up. Tumor response is clinically relevant, but by itself it does not show whether patients lived longer or remained progression-free for longer.
The researchers measured the percentages of CD3, CD4 and CD8 lymphocytes, the CD4/CD8 ratio, and natural killer cell activity. After treatment, the mean CD4 value in the treatment group increased from 31.07 to 35.58, the CD4/CD8 ratio increased from 1.40 to 1.53, and the NK-cell index increased from 37.58 to 40.28. In the control group, chemotherapy was followed by decreases in CD3, CD4, the CD4/CD8 ratio and NK cells. The authors reported statistical significance for some of these comparisons.
This is an interesting direction because chemotherapy can affect blood cells and immune function. However, an immunological biomarker is not the same as a demonstrated clinical benefit. An increase in the percentage of certain cells does not automatically mean fewer severe infections, shorter hospital stays or longer survival. A responsible interpretation of “Camelyn M2 and chemotherapy” should therefore clearly separate laboratory findings from patient-important outcomes.
The report used the Karnofsky scale, which describes a patient’s ability to carry out normal daily activities. Scores range from 0 to 100, with higher values indicating greater independence and functional ability. In the treatment group, the score improved in 30 patients, remained stable in 25 and worsened in three. In the control group, it improved in eight patients, remained stable in 31 and worsened in 21. The report states that the difference between the groups was statistically significant.
The researchers also analyzed changes in body weight of more than one kilogram. In the treatment group, weight increased in 25 patients, remained stable in 20 and decreased in 13. In the control group, the corresponding numbers were eight, 15 and 37. Body weight is an imperfect measure, however. It can change because of hydration, edema or ascites and does not replace a detailed assessment of nutritional status and muscle mass.
Blood counts: why might this result matter?
Chemotherapy can reduce white blood cells, red blood cells and platelets. The report compared toxicity grades for hemoglobin, leukocytes and platelets. In many categories, more severe abnormalities were numerically less common in the treatment group than in the control group. The authors concluded that better preservation of the blood count made it easier to complete chemotherapy on schedule.
In clinical practice, blood results must always be interpreted in the context of the specific regimen, dose, timing within the treatment cycle, coexisting conditions and symptoms. A table from a single report cannot predict how an individual patient will respond. It should also not lead anyone to start the product without discussing it with the treating oncology team.
The first limitation is the small sample size and the wide variety of cancers included. Breast cancer, lung cancer, lymphoma and liver cancer differ in biology, treatment and prognosis. Combining them in one analysis makes it difficult to determine in which specific group the observed signal may have been strongest. The report also does not provide separate results for each diagnosis.
The second limitation is the lack of methodological detail expected in a modern clinical publication. There is no sample-size calculation, detailed statistical analysis plan, trial registration information, participant flow diagram or transparent discussion of missing data. The report also does not describe systematic monitoring and reporting of all adverse events according to current standards.
The third limitation is the age of the document and the absence of confirmation in a large, multicenter, independent study. Scientific confidence grows when similar results are reproduced by different teams and evaluated in peer-reviewed publications. For this reason, the report should be treated as hypothesis-generating evidence that may justify further research, not as the final word on the subject.
A responsible summary is as follows: in the study described, the group receiving Kamelin-M2 together with chemotherapy had a higher CR+PR response rate than the group receiving chemotherapy alone. The authors also reported more favorable changes in selected immune markers, Karnofsky performance status, body weight and blood counts. At the same time, the study design and reporting do not provide enough evidence to establish the product’s anticancer efficacy.
In Poland, Camelyn M2 is presented on the product website as a dietary supplement. A supplement is not a substitute for a medicine or for standard cancer therapy. Marketing or blog content should not attribute to it the ability to treat or prevent disease, or guarantee improvement. It is reasonable, however, to describe the study accurately, present the results and explain why further verification is needed.
A patient can bring the full ingredient list, dosage information and a link to the report to the appointment. Useful questions include whether any ingredients could affect drug metabolism, blood clotting, the liver, the kidneys or the action of a specific chemotherapy regimen. The oncology team should be informed about all supplements, herbs and natural products, even when they appear harmless. “Natural” describes origin, not predictable action or freedom from interactions.
It is also helpful to agree on what will be monitored and which warning signs would mean the supplement should be stopped. Particular caution is advisable for people with allergies to bee products, bleeding disorders, liver or kidney disease, or those taking multiple medicines. Any decision must be individualized, with effective and safe cancer treatment remaining the priority.
The phrase “Camelyn M2 and chemotherapy” should not lead to a simplistic conclusion that the product either “works” or “does not work.” The Batumi report describes favorable differences between groups and deserves discussion. Its greatest value, however, lies in an interpretation that shows both the numbers and the limits of what can be inferred from them. Patients need information that is calm, understandable and honest: the findings are a potentially encouraging signal, but they require confirmation, and the product must not replace treatment recommended by an oncologist.
Frequently asked questions
Does the study prove that Camelyn M2 treats cancer?
No. The study compared chemotherapy alone with chemotherapy supplemented by the product. The results indicate differences in tumor response and selected parameters, but they do not provide complete survival data or independent confirmation.
That is not a safe approach. Natural products and supplements can interact with anticancer medicines. The oncologist should know the full list of products being taken.
The study can be treated as a reason to discuss the product with a doctor and as a basis for further research, not as an instruction for self-treatment. Standard oncological therapy remains the foundation of care.
When reading health information online, pause and ask a few questions. Does the article provide the full source, the number of participants and the way the groups were created? Does the result concern the product alone, or the product added to standard treatment? Are both benefits and adverse effects reported? Does the author distinguish a laboratory result from an outcome that matters directly to patients? In discussions of “Camelyn M2 and chemotherapy,” these questions help prevent an interesting observation from becoming a promise that the study does not support.
It is also worth checking the date of the study, the cancer type, the disease stage and the treatment regimen. A result obtained in a mixed group may not apply to a specific patient. The next step is a discussion with the oncologist, including the product composition, dosage and original source. The doctor can assess possible interactions, liver and kidney function, blood results and the priorities of treatment.
The most responsible decision is neither automatic rejection nor uncritical acceptance. It is an assessment of the level of certainty. The Batumi report provides specific figures and signals that may deserve further research, but it does not resolve every question. This is how a good science-based article should work: explain the data, name the uncertainty and help readers prepare for an informed medical consultation.
Report from the Adjara Oncology Center: Kamelin-M2 in combination with chemotherapy
National Cancer Institute: interactions between cancer therapies, supplements and food
National Cancer Institute: definition of the Karnofsky Performance Status Scale
European Commission: rules on nutrition and health claims
Safety note: This material is educational and does not constitute medical advice. It does not replace diagnosis or treatment recommended by a physician. Every supplement or supportive product used during cancer therapy should be discussed with an oncologist or clinical pharmacist because of possible interactions and contraindications.
